Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.49 |
| ▸ | KDM5C | P41229 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 5/20 | 0.46 |
| ▸ | KDM3A | Q9Y4C1 | 5/20 | 0.46 |
| ▸ | KDM6B | O15054 | 4/20 | 0.46 |
| ▸ | KDM4A | O75164 | 4/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 3/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.46 |
| ▸ | ALKBH5 | Q6P6C2 | 2/20 | 0.46 |
| ▸ | TET3 | O43151 | 1/20 | 0.46 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | ASPH | Q12797 | 1/20 | 0.46 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.46 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.46 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.46 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25985199 | 0.79 | KDM4C (0.50) | KDM4CKDM5CKDM4EKDM2AKDM3A | |
| SCHEMBL31032217 | 0.79 | KDM4C (0.50) | KDM4CKDM5CKDM4EKDM2AKDM3A | |
| SCHEMBL30701650 | 0.77 | KCNJ6 (0.37) | KDM4CKDM4EALDH1A1PIK3CAKCNJ6 | |
| SCHEMBL27357711 | 0.77 | KCNJ6 (0.35) | KDM4CPIK3CAKCNJ6KCNJ5KCNJ3 | |
| SCHEMBL30908333 | 0.76 | P4HA1 (0.46) | ALDH1A1MAPTGABRPGABRDGABRA1 | |
| SCHEMBL29990008 | 0.76 | P4HA1 (0.46) | ALDH1A1MAPTGABRPGABRDGABRA1 | |
| SCHEMBL31229393 | 0.74 | KDM4C (0.49) | KDM4CKDM5CKDM4EKDM2AKDM3A | |
| SCHEMBL24462402 | 0.72 | KDM4C (0.46) | KDM4CKDM5CKDM4EKDM2AKDM3A | |
| SCHEMBL16094931 | 0.72 | KDM4C (0.46) | KDM4CKDM5CKDM4EKDM2AKDM3A | |
| SCHEMBL12310375 | 0.72 | KDM4C (0.46) | KDM4CKDM5CKDM4EKDM2AKDM3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074828-B | Compounds and compositions as RAF kinase inhibitors | 诺华股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| EP-3191478-B1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | NOVARTIS AG (CH) | 2019-01-01 | — | — | US | disclosed |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | NOVARTIS AG (CH) | 2019-01-01 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| CN-107074828-A | Compounds and compositions as raf kinase inhibitors | 诺华股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-3191478-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | Novartis AG (CH) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016038582-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDM4C 2617/4885KDM5C 2628/4885KDM4E 2165/4885 |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | BRAF, RAF1, ARAF | KDM4C 2617/4885KDM5C 2628/4885KDM4E 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.